GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lantheus Holdings Inc (NAS:LNTH) » Definitions » Cyclically Adjusted Price-to-FCF

LNTH (Lantheus Holdings) Cyclically Adjusted Price-to-FCF : 34.59 (As of Jun. 02, 2025)


View and export this data going back to 2015. Start your Free Trial

What is Lantheus Holdings Cyclically Adjusted Price-to-FCF?

As of today (2025-06-02), Lantheus Holdings's current share price is $77.13. Lantheus Holdings's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 was $2.23. Lantheus Holdings's Cyclically Adjusted Price-to-FCF for today is 34.59.

The historical rank and industry rank for Lantheus Holdings's Cyclically Adjusted Price-to-FCF or its related term are showing as below:

LNTH' s Cyclically Adjusted Price-to-FCF Range Over the Past 10 Years
Min: 33.12   Med: 53.55   Max: 88.76
Current: 33.85

During the past years, Lantheus Holdings's highest Cyclically Adjusted Price-to-FCF was 88.76. The lowest was 33.12. And the median was 53.55.

LNTH's Cyclically Adjusted Price-to-FCF is ranked worse than
53.99% of 326 companies
in the Drug Manufacturers industry
Industry Median: 31.13 vs LNTH: 33.85

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Lantheus Holdings's adjusted free cash flow per share data for the three months ended in Mar. 2025 was $1.383. Add all the adjusted free cash flow per share for the past 10 years together and divide 10 will get our Cyclically Adjusted FCF per Share, which is $2.23 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Lantheus Holdings Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Lantheus Holdings's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lantheus Holdings Cyclically Adjusted Price-to-FCF Chart

Lantheus Holdings Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 52.32 41.33 41.60

Lantheus Holdings Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 36.43 44.20 57.64 41.60 43.74

Competitive Comparison of Lantheus Holdings's Cyclically Adjusted Price-to-FCF

For the Drug Manufacturers - Specialty & Generic subindustry, Lantheus Holdings's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lantheus Holdings's Cyclically Adjusted Price-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Lantheus Holdings's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Lantheus Holdings's Cyclically Adjusted Price-to-FCF falls into.


;
;

Lantheus Holdings Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Lantheus Holdings's Cyclically Adjusted Price-to-FCF for today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/ Cyclically Adjusted FCF per Share
=77.13/2.23
=34.59

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lantheus Holdings's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Lantheus Holdings's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2025 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=1.383/134.9266*134.9266
=1.383

Current CPI (Mar. 2025) = 134.9266.

Lantheus Holdings Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201506 -0.744 100.684 -0.997
201509 0.101 100.392 0.136
201512 0.259 99.792 0.350
201603 0.070 100.470 0.094
201606 0.553 101.688 0.734
201609 0.397 101.861 0.526
201612 0.276 101.863 0.366
201703 0.016 102.862 0.021
201706 0.441 103.349 0.576
201709 0.315 104.136 0.408
201712 0.185 104.011 0.240
201803 -0.071 105.290 -0.091
201806 0.372 106.317 0.472
201809 0.489 106.507 0.619
201812 0.251 105.998 0.320
201903 -0.002 107.251 -0.003
201906 0.438 108.070 0.547
201909 0.574 108.329 0.715
201912 0.441 108.420 0.549
202003 0.167 108.902 0.207
202006 -0.102 108.767 -0.127
202009 0.072 109.815 0.088
202012 -0.048 109.897 -0.059
202103 0.108 111.754 0.130
202106 0.344 114.631 0.405
202109 0.028 115.734 0.033
202112 0.138 117.630 0.158
202203 0.101 121.301 0.112
202206 0.964 125.017 1.040
202209 1.231 125.227 1.326
202212 1.424 125.222 1.534
202303 1.466 127.348 1.553
202306 -0.605 128.729 -0.634
202309 1.458 129.860 1.515
202312 1.429 129.419 1.490
202403 1.697 131.776 1.738
202406 0.645 132.554 0.657
202409 2.180 133.029 2.211
202412 1.947 133.157 1.973
202503 1.383 134.927 1.383

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Lantheus Holdings  (NAS:LNTH) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Lantheus Holdings Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Lantheus Holdings's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Lantheus Holdings Business Description

Traded in Other Exchanges
Address
201 Burlington Road, South Building, Bedford, MA, USA, 01730
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.
Executives
Marshall Robert J. Jr. officer: CFO and Treasurer C/O LANTHEUS MEDICAL IMAGING, INC., 331 TREBLE COVE ROAD, NORTH BILLERICA MA 01862
Mary Anne Heino director, officer: CEO and President C/O LANTHEUS HOLDINGS, INC., 331 TREBLE COVE ROAD, NORTH BILLERICA NY 01862
Paul Blanchfield officer: Chief Commercial Officer C/O LANTHEUS HOLDINGS, INC., 331, NORTH BILLERICA MA 01862
James H Thrall director 343 COMMERCIAL STREET #314, BOSTON MA 02109
Daniel Niedzwiecki officer: See Remarks C/O LANTHEUS HOLDINGS, INC., 331 TREBLE COVE ROAD, NORTH BILLERICA MA 01862
Gerard Ber director C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, 33RD FLOOR, NEW YORK NY 10169
Andrea Sabens officer: Chief Accounting Officer C/O LANTHEUS HOLDINGS, INC., 331 TREBLE COVE ROAD, NORTH BILLERICA MA 01862
Gary J Pruden director ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Heinz Christoph Maeusli director SCHUETZENWEG 3, ENGELBURG V8 9032
Julie Mchugh director C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Sam R Leno director C/O BOSTON SCIENTIFIC CORPORATION, ONE BOSTON SCIENTIFIC PLACE, NATICK MA 01760
Minnie Baylor-henry director C/O SCPHARMACUETICALS, INC., 2400 DISTRICT AVENUE SUITE 310, BURLINGTON MA 01803
Etienne Montagut officer: See Remarks C/O LANTHEUS HOLDINGS, INC., 331 TREBLE COVE ROAD, NORTH BILLERICA MA 01862
Brian A Markison director 501 FIFTH STREET, BRISTOL TN 37620
Jean-claude Provost officer: Chief Medical Officer C/O LANTHEUS HOLDINGS, INC., 201 BURLINGTON RD, SOUTH BUILDING, BEDFORD MA 01730